Purple Book reference family · 351(a) biologic
bimekizumab-bkzx (Bimzelx)
bimekizumab-bkzx is an FDA-licensed reference biologic from UCB, Inc..
351(a) biologicBLA 761151 UCB, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2024
Reference product
Originator biologic
351(a)BLA 761151
Bimzelx bimekizumab-bkzx
UCB, Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
RCSB Protein Data Bank
Experimental 3D structure for bimekizumab-bkzx from the RCSB Protein Data Bank (PDB 9SGH).
Interactive biological assembly from PDB entry 9SGH. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference bimekizumab-bkzx product.
1 yr 11 mo ago
bimekizumab-bkzx: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for bimekizumab-bkzx.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
